Stockreport

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights [Yahoo! Finance]

IO Biotech, Inc.  (IOBT) 
PDF KEYTRUDA ® (pembrolizumab) in patients with advanced melanoma on track with primary endpoint of progression free survival (PFS) projected to be reached in first half of [Read more]